Literature DB >> 19962288

A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder.

H Woelk1, S Schläfke.   

Abstract

Generalized and persistent anxiety, accompanied by nervousness and other symptoms (Generalised Anxiety Disorder, GAD) is frequent in the general population and leads to benzodiazepine usage. Unfortunately, these substances induce sedation and have a high potential for drug abuse, and there is thus a need for alternatives. As the anxiolytic properties of lavender have already been demonstrated in pharmacological studies and small-scale clinical trials, it was postulated that lavender has a positive effect in GAD. A controlled clinical study was then performed to evaluate the efficacy of silexan, a new oral lavender oil capsule preparation, versus a benzodiazepine. In this study, the efficacy of a 6-week-intake of silexan compared to lorazepam was investigated in adults with GAD. The primary target variable was the change in the Hamilton Anxiety Rating Scale (HAM-A-total score) as an objective measurement of the severity of anxiety between baseline and week 6. The results suggest that silexan effectively ameliorates generalized anxiety comparable to a common benzodiazepine (lorazepam). The mean of the HAM-A-total score decreased clearly and to a similar extent in both groups (by 11.3+/-6.7 points (45%) in the silexan group and by 11.6+/-6.6 points (46%) in the lorazepam group, from 25+/-4 points at baseline in both groups). During the active treatment period, the two HAM-A subscores "somatic anxiety" (HAM-A subscore I) and "psychic anxiety" (HAM-A subscore II) also decreased clearly and to a similar extent in both groups. The changes in other subscores measured during the study, such as the SAS (Self-rating Anxiety Scale), PSWQ-PW (Penn State Worry Questionnaire), SF 36 Health survey Questionnaire and Clinical Global Impressions of severity of disorder (CGI item 1, CGI item 2, CGI item 3), and the results of the sleep diary demonstrated comparable positive effects of the two compounds. In conclusion, our results demonstrate that silexan is as effective as lorazepam in adults with GAD. The safety of silexan was also demonstrated. Since lavender oil showed no sedative effects in our study and has no potential for drug abuse, silexan appears to be an effective and well tolerated alternative to benzodiazepines for amelioration of generalised anxiety. Copyright 2009 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19962288     DOI: 10.1016/j.phymed.2009.10.006

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  27 in total

Review 1.  Biological Activities of Essential Oils: From Plant Chemoecology to Traditional Healing Systems.

Authors:  Javad Sharifi-Rad; Antoni Sureda; Gian Carlo Tenore; Maria Daglia; Mehdi Sharifi-Rad; Marco Valussi; Rosa Tundis; Marzieh Sharifi-Rad; Monica R Loizzo; Adedayo Oluwaseun Ademiluyi; Razieh Sharifi-Rad; Seyed Abdulmajid Ayatollahi; Marcello Iriti
Journal:  Molecules       Date:  2017-01-01       Impact factor: 4.411

Review 2.  Characterization of anxiolytic and neuropharmacological activities of Silexan.

Authors:  Vikas Kumar
Journal:  Wien Med Wochenschr       Date:  2013-01-30

Review 3.  Herbal medicine for depression and anxiety: A systematic review with assessment of potential psycho-oncologic relevance.

Authors:  K Simon Yeung; Marisol Hernandez; Jun J Mao; Ingrid Haviland; Jyothirmai Gubili
Journal:  Phytother Res       Date:  2018-02-21       Impact factor: 5.878

Review 4.  Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder - evidence from clinical trials.

Authors:  Siegfried Kasper; Markus Gastpar; Walter E Müller; Hans-Peter Volz; Hans-Jürgen Möller; Angelika Dienel; Sandra Schläfke
Journal:  Wien Med Wochenschr       Date:  2010-12

Review 5.  Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review.

Authors:  Jeffrey R Strawn; Laura Geracioti; Neil Rajdev; Kelly Clemenza; Amir Levine
Journal:  Expert Opin Pharmacother       Date:  2018-07       Impact factor: 3.889

6.  Phytopharmaceutical treatment of anxiety, depression, and dementia in the elderly: evidence from randomized, controlled clinical trials.

Authors:  Siegfried Kasper
Journal:  Wien Med Wochenschr       Date:  2015-06-20

Review 7.  Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression.

Authors:  Ioline D Henter; Rafael T de Sousa; Philip W Gold; Andre R Brunoni; Carlos A Zarate; Rodrigo Machado-Vieira
Journal:  Expert Rev Clin Pharmacol       Date:  2017-01-16       Impact factor: 5.045

Review 8.  The impact of medication on health-related quality of life in patients with generalized anxiety disorder.

Authors:  Hilary Wilson; Sally Mannix; Hafiz Oko-osi; Dennis A Revicki
Journal:  CNS Drugs       Date:  2015-01       Impact factor: 5.749

9.  The diagnosis and treatment of generalized anxiety disorder.

Authors:  Borwin Bandelow; Reinhard Boerner J; Siegfried Kasper; Michael Linden; Hans-Ulrich Wittchen; Hans-Jürgen Möller
Journal:  Dtsch Arztebl Int       Date:  2013-04-26       Impact factor: 5.594

Review 10.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.